Online Inquiry
Fas Antibody
SPA-03811
| Size | Price |
| 25 µg | Online Inquiry |
| 100 µg | Online Inquiry |
| More Options | Online Inquiry |
| Target Information | |
|---|---|
| Target Name | Fas |
| Gene Abbr. | FAS |
| Gene ID | 355 |
| Full Name | Fas cell surface death receptor |
| Alias | ALPS1A, APO-1, APT1, CD95, FAS1 |
| Introduction | Association of the receptor Fas with its ligand FasL triggers an apoptotic pathway that plays an important role in immune regulation, development, and progression of cancers. Loss of function mutation in either Fas (lpr mice) or FasL (gld mice) leads to lymphadenopathy and splenomegaly as a result of decreased apoptosis in CD4-CD8- T lymphocytes. FasL (CD95L, Apo-1L) is a type II transmembrane protein of 280 amino acids (runs at approximately 40 kDa upon glycosylation) that belongs to the TNF family, which also includes TNF-α, TRAIL, and TWEAK. Binding of FasL to its receptor triggers the formation of a death-inducing signaling complex (DISC) involving the recruitment of the adaptor protein FADD and caspase-8. Activation of caspase-8 from this complex initiates a caspase cascade resulting in the activation of caspase-3 and subsequent cleavage of proteins leading to apoptosis. Unlike Fas, which is constitutively expressed by various cell types, FasL is predominantly expressed on activated T lymphocytes, NK cells, and at immune privileged sites. FasL is also expressed in several tumor types as a mechanism to evade immune surveillance. Similar to other members of the TNF family, FasL can be cleaved by metalloproteinases producing a 26 kDa trimeric soluble form. |
| Product Details | |
|---|---|
| Host | Rabbit |
| Clonality | Monoclonal |
| Clone No. | R-125224 |
| Isotype | IgG Kappa |
| Immunogen | R-125224 is generated by the humanization of the murine HFE7A anti-Fas/TNFRSF6/CD95 antibody by grafting the CDR regions to the framework regions of the human 8E10 antibody and substituting key framework residues from the murine antibody into the 8E10 sequence. The original HFE7A was derived from a hybridoma cell line generated by the fusion of NS1 myeloma cells with splenocytes from Fas-deficient mice which had been immunized with partially purified recombinant human Fas-AIC2A chimera protein consisting of the extracellular region of human Fas/TNFRSF6/CD95 antigen (aa -16 to 150) and the extracellular region of the murine IL-3 receptor AIC2 (aa 3-423). The HFE7A hybridoma was selected after screening by flow cytometry for the production of antibodies with the ability to bind to the WR19L12a transformed murine T cell lymphoma cell line expressing human Fas/TNFRSF6/CD95 or the L5178YA1 cell line expressing murine Fas/TNFRSF6/CD95, but not to the parental WR19L or L5178Y cells. |
| Usage | |
|---|---|
| Application | WB, ELISA, FC, IF |
| MW(KDa) | 40-50 |
| Reactivity | Human |
| Specificity | R-125224 binds to the extracellular portion of human Fas/TNFRSF6/CD95 at an eptiope consisting of the sequence RTQNTKCRCK (aa 105-114) (pmid: 11754745). Fas is a type I membrane protein which belongs to the tumor necrosis factor (TNF) receptor/nerve growth factor (NGF) receptor superfamily. It is able to transduce apoptotic signals into the cell when bound by its ligand FasL (Fas ligand), which is primarily expressed in activated T lymphoid-myeloid lineage cells, in the eye, in reproductive organs and in some tumors. The Fas-FasL system is known to play an important role in maintaining the immune system as mice with Fas-defective lymphoproliferation (lpr) and FasL-defective generalized lymphoproliferative disease (gld) mutations develop massive lymphadenopathy and autoimmune diseases. |
| Storage & Handling | |
|---|---|
| Storage Buffer | PBS. |
| Preservative | 0.02% Proclin 300 |
| Storage Temp. | Store at 4 °C for up to 3 months. For longer storage, aliquot and store at -20 °C. |
For research use only. Not intended for any clinical use. No products from CD BioSciences may be resold, modified for resale or used to manufacture commercial products without prior written approval from CD BioSciences.